|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
$0.06 0.00 (0.00%) as of 4:30 Fri 6/3
|
|
Download |
|
|
| |
| |
| Exchange: |
OTC Bulletin Board |
| Security
Type: |
Common |
| Shares
Out: |
66,230,000 |
| Market
Cap: |
4.11(M) |
| Last
Volume: |
362,100 |
Avg
Vol: |
361,099 |
| 52
Week Range: |
$0.062 - $0.062 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Advaxis is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Listeria monocytogenes (Lm) Technology antigen delivery products based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. Co.'s pipeline of product candidates include: ADXS-503, which is for the cancer indication of non-small cell lung cancer in combination with KEYTRUDA® (pembrolizumab); ADXS-504, which is for the cancer indication of early stage prostate cancer; and ADXS-PSA, which is for the cancer indication of metastatic prostate cancer in combination with KEYTRUDA® (pembrolizumab).
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
1,317,716 |
1,317,716 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
1 |
1 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  French Christy Lee |
VP-Regulatory, Medical Affairs |
• – – |
2014-07-01 |
4 |
D |
$3.15 |
$189 |
D/D |
(60) |
79,102 |
|
- |
|
| French Christy Lee |
VP-Regulatory, Medical Affairs |
• – – |
2014-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
503 |
79,162 |
|
- |
|
| Petit Robert |
Chief Scientific Officer |
• – – |
2014-07-01 |
4 |
D |
$3.15 |
$665 |
D/D |
(211) |
119,883 |
|
- |
|
| Petit Robert |
Chief Scientific Officer |
• – – |
2014-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,183 |
120,094 |
|
- |
|
| Berman Richard J |
Director |
– • – |
2014-05-09 |
4 |
S |
$2.63 |
$38,247 |
D/D |
(14,530) |
0 |
|
- |
|
| French Christy Lee |
Exec. Dir. of Medical Affairs |
• – – |
2014-05-01 |
4 |
D |
$2.72 |
$408 |
D/D |
(150) |
78,659 |
|
- |
|
| French Christy Lee |
Exec. Dir. of Medical Affairs |
• – – |
2014-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
874 |
78,809 |
|
- |
|
| Mayes Gregory T. |
Chief Operating Officer |
• – – |
2014-05-01 |
4 |
D |
$2.72 |
$1,219 |
D/D |
(448) |
133,471 |
|
- |
|
| Mayes Gregory T. |
Chief Operating Officer |
• – – |
2014-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,686 |
133,919 |
|
- |
|
| Petit Robert |
Chief Scientific Officer |
• – – |
2014-05-01 |
4 |
D |
$2.72 |
$1,205 |
D/D |
(443) |
118,911 |
|
- |
|
| Petit Robert |
Chief Scientific Officer |
• – – |
2014-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
2,055 |
119,354 |
|
- |
|
| Bonstein Sara |
Chief Financial Officer |
• • – |
2014-05-01 |
4 |
D |
$2.72 |
$528 |
D/D |
(194) |
522 |
|
- |
|
| Bonstein Sara |
Chief Financial Officer |
• • – |
2014-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
716 |
716 |
|
- |
|
| O'connor Daniel |
Chief Executive Officer |
• • – |
2014-05-01 |
4 |
D |
$2.72 |
$6,457 |
D/D |
(2,374) |
315,535 |
|
- |
|
| O'connor Daniel |
Chief Executive Officer |
• • – |
2014-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
6,893 |
317,909 |
|
- |
|
465 Records found
|
|
Page 19 of 19 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
